Value in Oncology
Transition from Branded to Generic Cancer Drugs Significantly Increases Treatment Cost-Effectiveness
An economic analysis of oncology regimens that were previously evaluated in trials conducted by the Canadian Cancer Society Research Institute has shown that the transition from branded to generic drug costs has a considerable impact on the cost-effectiveness and cost-utility of treatment.
In addition to affecting patient well-being and quality of life, financial toxicity has been shown to worsen survival outcomes because of nonadherence to drug therapy. Although policy interventions, improvements in benefit designs, and adjustments to reimbursement may help reduce costs for patients in the long-term, immediate changes are needed to alleviate financial burden, said Yousuf Zafar, MD, MHS, of the Duke Cancer Institute, Durham, NC, at ASCO 2016.
The cost of care varies widely across breast cancer chemotherapy regimens, even among treatments of comparable efficacy, according to a retrospective study presented at ASCO 2016. Some of the most costly regimens, such as docetaxel plus doxorubicin and cyclophosphamide, were found to be the most expensive and were associated with the highest risk for hospitalization.
Costs of Treatment-Related Adverse Events Higher with Docetaxel than with Nivolumab in Advanced Lung Cancer
The results of 2 phase 3 trials on treatment-related adverse events (AEs) in patients with non–small-cell lung cancer (NSCLC) showed that their frequency and associated costs were significantly higher with docetaxel than with nivolumab. The results were presented at ASCO 2016.
Evidence-based treatment protocols and clinical pathways for delivering quality cancer care have been developed for virtually all tumor types and stages, but questions remain regarding patient access, care quality, and transparency in their development and implementation.
A study evaluating the economic burden associated with multiple myeloma and its treatment has found that routine management and disease progression continues to drive healthcare resource utilization, regardless of the number of previous lines of therapy. Other key drivers of healthcare utilization in multiple myeloma are hospitalizations, transplantations, and concomitant medication use. The study was presented at ASCO 2016.
With $137 billion and growing spent on treatment in the US healthcare annually, cancer care delivery poses a significant challenge.
Medicare has initiated several programs in the past decade to encourage value, but questions remain regarding their effectiveness.
Redesigning the Payment Model for Acute Leukemia: Benefits and Challenges of the Episode-of-Care Model
Given the high cost of care for acute leukemia, innovative payment strategies that reward longitudinal care and create economic incentives for data-driven care delivery are needed.
Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination.
Page 2 of 3
Results 11 - 20 of 30
Results 11 - 20 of 30